Nisa Investment Advisors LLC Has $924,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nisa Investment Advisors LLC boosted its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 639.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 20,343 shares of the company's stock after buying an additional 17,592 shares during the quarter. Nisa Investment Advisors LLC's holdings in Janux Therapeutics were worth $924,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of JANX. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Janux Therapeutics by 61.1% during the 2nd quarter. Amalgamated Bank now owns 970 shares of the company's stock valued at $41,000 after buying an additional 368 shares during the period. Summit Securities Group LLC purchased a new position in shares of Janux Therapeutics during the 2nd quarter valued at $29,000. Plato Investment Management Ltd acquired a new position in shares of Janux Therapeutics in the second quarter worth $42,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics during the second quarter worth $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Stock Down 1.1 %

JANX stock traded down $0.64 during midday trading on Tuesday, reaching $55.23. 280,916 shares of the company's stock traded hands, compared to its average volume of 710,909. The company has a 50-day simple moving average of $48.28 and a two-hundred day simple moving average of $46.19. Janux Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $65.60. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -59.98 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. The business's revenue was up 709.1% compared to the same quarter last year. Equities research analysts forecast that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on JANX shares. Stifel Nicolaus started coverage on Janux Therapeutics in a report on Friday, September 6th. They set a "buy" rating and a $70.00 price target for the company. Scotiabank decreased their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating for the company in a research report on Friday, August 9th. Wedbush reaffirmed an "outperform" rating and issued a $74.00 price objective on shares of Janux Therapeutics in a research note on Thursday, August 8th. UBS Group started coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $69.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $63.00 price objective on shares of Janux Therapeutics in a report on Monday, August 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Janux Therapeutics has an average rating of "Moderate Buy" and an average price target of $66.44.

Insiders Place Their Bets

In related news, insider Andrew Hollman Meyer sold 50,000 shares of the firm's stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 50,000 shares of the company's stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the completion of the transaction, the insider now owns 67,592 shares of the company's stock, valued at $3,106,528.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the sale, the chief executive officer now owns 307,054 shares in the company, valued at $14,219,670.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 420,610 shares of company stock worth $19,288,666 over the last ninety days. 29.40% of the stock is currently owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.